Patent details
EP3337828 Title: ANTI-PCSK9 INHIBITORY ANTIBODIES FOR TREATING PATIENTS WITH HYPERLIPIDEMIA UNDERGOING LIPOPROTEIN APHERESIS
Basic Information
- Publication number:
- EP3337828
- PCT Application Number:
- US2016047257
- Type:
- European Patent Granted for LU
- Legal Status:
- Unitary Effect Registered
- Application number:
- EP167580190
- PCT Publication Number:
- WO2017031151
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- ANTI-PCSK9 INHIBITORY ANTIBODIES FOR TREATING PATIENTS WITH HYPERLIPIDEMIA UNDERGOING LIPOPROTEIN APHERESIS
- French Title of Invention:
- ANTICORPS INHIBITEURS ANTI-PCSK9 DESTINÉS AU TRAITEMENT DES PATIENTS ATTEINTS D'HYPERLIPIDÉMIE SUBISSANT UNE APHÉRÈSE DE LIPOPROTÉINES
- German Title of Invention:
- ANTI-PCSK9-HEMMERANTIKÖRPER ZUR BEHANDLUNG VON PATIENTEN MIT HYPERLIPIDÄMIE, DIE EINER LIPOPROTEINAPHERESE UNTERZOGEN WERDEN
- SPC Number:
Unitary Effect
- Unitary Effect Requested:
- Yes
- Unitary Effect Request Filing Date:
- 23/09/2025
- Link to UPP Register:
- European Patent Register
- Unitary Effect Request Withdrawal Date:
- Unitary Effect Status:
- Unitary Effect Registered
- Unitary Effect Acceptance Decision Date:
- 30/09/2025
- Unitary Effect Rejection Decision Date:
- Unitary Effect Date:
- 27/08/2025
- Unitary Effect Registration Date:
- 30/09/2025
- Unitary Effect Re-establishment of rights Filing Date:
- Unitary Effect Re-establishment of rights EPO Decision :
- Unitary Effect Re-establishment of rights EPO Decision Date:
- Explanatory Text UE:
- Safety Net Request Date:
- Safety Net Decision Date:
- Safety Net Decision Outcome:
- SPC Number:
Dates
- Filing date:
- 17/08/2016
- Grant date:
- 27/08/2025
- EP Publication Date:
- 27/06/2018
- PCT Publication Date:
- 23/02/2017
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 27/08/2025
- EP B1 Publication Date:
- 27/08/2025
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 17/08/2036
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 20/08/2025
- Name:
- Regeneron Pharmaceuticals, Inc.
- Address:
- 777 Old Saw Mill River Road, Tarrytown, NY 10591, United States (US)
Inventor
1
- Name:
- PORDY, Robert C.
- Address:
- United States (US)
2
- Name:
- MANVELIAN, Garen
- Address:
- United States (US)
Priority
1
- Priority Number:
- 201562206326 P
- Priority Date:
- 18/08/2015
- Priority Country:
- United States (US)
2
- Priority Number:
- 201562264361 P
- Priority Date:
- 08/12/2015
- Priority Country:
- United States (US)
3
- Priority Number:
- 201562270790 P
- Priority Date:
- 22/12/2015
- Priority Country:
- United States (US)
4
- Priority Number:
- 201662291571 P
- Priority Date:
- 05/02/2016
- Priority Country:
- United States (US)
5
- Priority Number:
- 201662311455 P
- Priority Date:
- 22/03/2016
- Priority Country:
- United States (US)
6
- Priority Number:
- 201662367374 P
- Priority Date:
- 27/07/2016
- Priority Country:
- United States (US)
Classification
- IPC classification:
- C07K 16/40; A61P 3/06; A61K 39/395; A61K 39/00;
Publication
European Patent Bulletin
1
- Issue number:
- 202535
- Publication date:
- 27/08/2025
- Description:
- Grant (B1)
2
- Issue number:
- 202544
- Publication date:
- 29/10/2025
- Description:
- Unitary Effect Request Receipt
3
- Issue number:
- 202544
- Publication date:
- 29/10/2025
- Description:
- Unitary Effect Request Acceptance
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|